Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) is a global biotechnology company dedicated to improving the lives of individuals living with rare and serious diseases. Founded in 1986, BioCryst specializes in designing, optimizing, and developing novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama, the company harnesses its expertise in drug discovery, clinical development, regulatory affairs, and product commercialization.
BioCryst is known for its flagship product, ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor specifically designed to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older. The efficacy of ORLADEYO has been demonstrated through multiple clinical studies and real-world data, showing significant reductions in HAE attack rates across various patient profiles.
The company's robust pipeline includes several innovative programs such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME). BioCryst's research spans multiple scientific disciplines, including biology, computer modeling, and medicinal chemistry, targeting therapeutic areas like acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.
In recent announcements, BioCryst reported strong financial performance with ORLADEYO net revenue experiencing substantial growth. The company also continues to expand globally, with recent approvals of ORLADEYO in major markets, including Brazil and Mexico. Partnerships with organizations such as Pint Pharma help BioCryst extend its reach and bring life-changing treatments to patients worldwide.
BioCryst remains committed to advancing its clinical programs, generating new compounds, and upholding a culture of engagement and accountability. The company's ongoing dedication to developing innovative therapeutics aims to address unmet medical needs and provide better health outcomes for patients suffering from rare and serious conditions.
For more information, please visit www.biocryst.com or follow them on LinkedIn.
BioCryst Pharmaceuticals has presented new real-world evidence indicating that ORLADEYO® (berotralstat) reduces attack rates in HAE patients with normal C1-inhibitor levels. A study involving six patients revealed that five experienced a 75-100% reduction in HAE attack rates after six months of treatment, with one patient showing a 29% reduction.
Additionally, new results highlight the adverse health outcomes associated with attenuated androgen use for HAE prophylaxis, emphasizing the need for safer, targeted therapies as recommended by EAACI guidelines. The study assessed 108 studies and found that adverse outcomes include increased cardiovascular events, liver damage, and cancer, reinforcing the importance of accessible, safer treatment options.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present new data on ORLADEYO® (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE), at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024. The company will present two abstracts: one on adverse health outcomes and perspectives of attenuated androgen use, and another on the effectiveness and safety of berotralstat in patients with HAE with normal C1 inhibitor. These presentations are scheduled for May 31 and June 2, 2024.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that COFEPRIS in Mexico approved ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The drug is now approved in four countries in the pan-Latin America region. BioCryst collaborates with Pint Pharma to bring the therapy to HAE patients in need.
BioCryst Pharmaceuticals, Inc. presented new real-world evidence demonstrating significant reductions in healthcare resource utilization (HRU) among patients with hereditary angioedema (HAE) in the United States after initiating ORLADEYO® (berotralstat) treatment. The study, presented at the 2024 ISPOR conference, highlighted reduced all-cause hospitalizations and angioedema-related hospitalizations, showcasing the cost-effectiveness and collective benefit of ORLADEYO therapy for patients and payers.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) will be presenting at various upcoming investor conferences in May and June 2024. The presentations will take place in New York and Las Vegas, offering investors insights into the company's latest developments and future prospects.
BioCryst Pharmaceuticals, Inc. reported a 30% y-o-y growth in ORLADEYO net revenue to $88.9 million in Q1 2024. The full-year 2024 ORLADEYO revenue guidance was adjusted to $390-$400 million, Pipeline programs advancing on schedule. Financial results showed total revenues of $92.8 million in Q1 2024, with an operating loss of $14.5 million. The company expects full-year 2024 operating expenses to be between $365 million and $375 million. BioCryst is confident in achieving a full-year operating profit in 2024 and positive cash flow in the second half of 2025.
BioCryst Pharmaceuticals, Inc. announced the granting of stock options and restricted stock units to 10 newly-hired employees as inducements for joining the company. The options have an exercise price of $4.13 per share, vesting in four annual installments over 10 years, subject to continued service.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
What is BioCryst Pharmaceuticals' main product?
Where is BioCryst Pharmaceuticals headquartered?
What therapeutic areas does BioCryst Pharmaceuticals focus on?
What recent achievements has BioCryst Pharmaceuticals reported?
How does ORLADEYO® work?
What is the pipeline of BioCryst Pharmaceuticals?
Who are BioCryst Pharmaceuticals' partners?
What is the company's approach to drug development?
What are some of the challenges BioCryst Pharmaceuticals addresses?
How can I stay updated on BioCryst Pharmaceuticals' latest news?
